"TARGET Study": Safety and Performance of the Cardiovalve TR Replacement System
TARGET
1 other identifier
interventional
100
1 country
7
Brief Summary
The objective of this study is to evaluate the safety and performance of Cardiovalve TR system
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2022
Longer than P75 for not_applicable
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 2, 2022
CompletedFirst Posted
Study publicly available on registry
August 4, 2022
CompletedStudy Start
First participant enrolled
December 9, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 15, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 15, 2033
January 5, 2026
December 1, 2025
3.7 years
August 2, 2022
December 31, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Freedom from device or procedure-related adverse events
Freedom from device or procedure-related adverse events
30 days
Reduction in TR grade
Reduction in TR in comparison to baseline
30 days
Secondary Outcomes (2)
Six minute walk test
30 days, 6 months, 12 months, annual for five years
KCCQ
30 days, 6 months, 12 months, annual for five years
Study Arms (1)
Cardiovalve TR replacement Group
EXPERIMENTALCardiovalve TR valve replacement System
Interventions
The Cardiovalve system includes a valve and delivery system, designed for replacement of the tricuspid valve through a transcatheter.
Eligibility Criteria
You may qualify if:
- Functional TR ≥3+
- Symptomatic, NYHA Class II-IVa
- Patient approved by the Subject Screening Committee
You may not qualify if:
- Cardiac anatomy deemed not suitable for the Cardiovalve TR system
- Hemodynamic instability
- Severe right ventricular failure
- Refractory heart failure requiring advanced intervention
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cardiovalve Ltd.lead
Study Sites (7)
Universität Bochum
Bad Oeynhausen, 32545, Germany
Charité university
Berlin, 10117, Germany
Uniklinik Bonn
Bonn, 53127, Germany
Herzzentrum Uniklinik
Cologne, 50937, Germany
Universitäres Herz
Hamburg, 20251, Germany
University Heart Center Lübeck
Lübeck, 20251, Germany
Universitätsklinikum - Regensburg
Regensburg, 93053, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Georg Nickenig, Dr
Bonn Clinic
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 2, 2022
First Posted
August 4, 2022
Study Start
December 9, 2022
Primary Completion (Estimated)
August 15, 2026
Study Completion (Estimated)
December 15, 2033
Last Updated
January 5, 2026
Record last verified: 2025-12